{"success":true,"data":{"pressRelease":{"id":"164837","rtpr_id":"nBw8qmNywa-20261008","ticker":"DNA","exchange":"NYSE","all_tickers":["DNA"],"title":"Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program","author":"Business Wire","published_at":"2026-10-08T20:10:00.254Z","article_body":"Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers,\nContributing Cloud Lab Time and Protein Testing Services to $1.5 Billion\nBreakthrough Science Program\n\nGinkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind\naccess to its autonomous laboratory in Boston to support the National Science\nFoundation’s X-Labs program. Ginkgo’s support was announced today by\nMichael Kratsios, Director of the White House Office of Science and Technology\nPolicy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C.\n\nNSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams\nof researchers, engineers, and entrepreneurs pursuing breakthrough science\nthrough milestone-based awards. Through its contribution, Ginkgo will make\ncloud lab time on its autonomous lab available to NSF X-Labs teams, giving\nresearchers remote access to robotic lab infrastructure to design, run, and\nanalyze experiments.\n\nAs part of the NSF X-Labs program, Ginkgo will offer NSF X-Labs teams its\nprotein testing services, enabling researchers to rapidly express and\ncharacterize protein designs, including those generated by AI models, without\nbuilding out their own wet lab capacity.\n\nGinkgo’s autonomous lab in Boston runs on Ginkgo’s Reconfigurable\nAutomation Carts (RACs), modular robots that combine robotic arms, maglev\nsample transport, and Catalyst software to run high-mix lab work around the\nclock. Researchers can access the lab remotely through Ginkgo Cloud Lab, which\nprovides access to a fleet of more than 70 instruments spanning sample\npreparation, liquid handling, analytical readouts, storage, and incubation.\n\nAutonomous labs are a key part of the U.S. government’s vision for American\nscience. Ginkgo already works with NSF through the Programmable Cloud\nLaboratories (PCL) Test Bed program, where it is expected to provide RACs and\nsoftware to cloud lab nodes at Caltech, the University of Maryland, and\nNorthwestern University.\n\n“Autonomous labs are a key part of the U.S. government’s vision for a\ngolden age of American science, and we’re proud to put our autonomous lab to\nwork for NSF X-Labs teams,” said Jason Kelly, co-founder and CEO of Ginkgo\nBioworks. “Robotic labs are key to competing with China and to improving the\nreproducibility and output of U.S. science. We believe robotic labs should be\nat every university and biopharma company, and programs like X-Labs show how\nquickly researchers can move when they have access to them.”\n\nResearchers interested in Ginkgo’s autonomous lab capabilities can learn\nmore and submit protocols at cloud.ginkgo.bio\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fcloud.ginkgo.bio&esheet=54618760&newsitemid=20261008805764&lan=en-US&anchor=cloud.ginkgo.bio&index=1&md5=1da2a01cb4a640608540c022c604b5b4)\n.\n\nAbout Ginkgo Bioworks\n\nGinkgo Bioworks builds the tools that make biology easier to engineer for\neveryone. The company offers autonomous laboratories that replace manual\nlaboratory work with robotics in the lab, greatly improving the productivity\nof scientists. Ginkgo’s in-house autonomous lab is also available as a\n“cloud lab” through our Datapoints and Solutions contract research\nservices. For more information, visit ginkgobioworks.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fginkgobioworks.com&esheet=54618760&newsitemid=20261008805764&lan=en-US&anchor=ginkgobioworks.com&index=2&md5=2759ac1223a0ab8755b1929795443cec)\nand ginkgobiosecurity.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fginkgobiosecurity.com&esheet=54618760&newsitemid=20261008805764&lan=en-US&anchor=ginkgobiosecurity.com&index=3&md5=d3cde321bb50c1570f0a2561c89c1593)\n, read our blog, or follow us on social media channels such as X (@Ginkgo and\n@Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or\nLinkedIn.\n\nForward-Looking Statements of Ginkgo Bioworks\n\nThis press release contains certain forward-looking statements within the\nmeaning of the federal securities laws, including statements regarding\nGinkgo’s support of the NSF X-Labs program and the capabilities and\npotential success of Ginkgo’s autonomous labs. These forward-looking\nstatements generally are identified by the words \"believe,\" \"can,\" \"project,\"\n\"potential,\" \"expect,\" \"anticipate,\" \"estimate,\" \"intend,\" \"strategy,\"\n\"future,\" \"opportunity,\" \"plan,\" \"may,\" \"should,\" \"will,\" \"would,\" \"will be,\"\n\"will continue,\" \"will likely result,\" and similar expressions.\nForward-looking statements are predictions, projections and other statements\nabout future events that are based on current expectations and assumptions\nand, as a result, are subject to risks and uncertainties. Many factors could\ncause actual future events to differ materially from the forward-looking\nstatements in this press release, including but not limited to: (i) our\nability to realize near-term and long-term cost savings associated with our\nsite consolidation plans, including the ability to terminate leases or find\nsub-lease tenants for unused facilities, (ii) volatility in the price of\nGinkgo's securities due to a variety of factors, including changes in the\ncompetitive and highly regulated industries in which Ginkgo operates and plans\nto operate, variations in performance across competitors, and changes in laws\nand regulations affecting Ginkgo's business, (iii) the ability to implement\nbusiness plans, forecasts, and other expectations, and to identify and realize\nadditional business opportunities, including with respect to our solutions and\ntools offerings, (iv) the risk of downturns in demand for products using\nsynthetic biology, (v) the uncertainty regarding the demand for passive\nmonitoring programs and biosecurity services, (vi) changes to the biosecurity\nindustry, including due to advancements in technology, emerging competition\nand evolution in industry demands, standards and regulations, (vii) the\noutcome of any pending or potential legal proceedings against Ginkgo, (viii)\nour ability to realize the expected benefits from and the success of our\nplatform programs and assets, (ix) our ability to successfully develop\nengineered cells, bioprocesses, data packages or other deliverables, (x) the\nproduct development, production or manufacturing success of our customers,\n(xi) our exposure to the volatility and liquidity risks inherent in holding\nequity interests in other operating companies and other non-cash consideration\nwe may receive for our services, (xii) the potential negative impact on our\nbusiness of our restructuring or the failure to realize the anticipated\nsavings associated therewith, (xiii) the uncertainty regarding government\nbudgetary priorities and funding allocated to government agencies, including\npotential adverse effects from the U.S. government shutdown, (xiv) our ability\nto scale, expand the capacity of, and continue to develop the capabilities of\nour autonomous lab (including Nebula) on the timelines and to the extent we\nanticipate, (xv) the pace and degree to which autonomous laboratory\ninfrastructure is adopted by, and displaces manual laboratory work in, the\nbroader life sciences and industrial biotechnology markets, (xvi) the actual\nsize, composition and growth of the addressable markets we target, which may\ndiffer materially from our estimates, (xvii) our ability to integrate our\nautonomous lab platform with third-party artificial intelligence models and\nother technologies, and the rate of development and adoption of such\ntechnologies, and (xviii) our ability to maintain and expand strategic\npartnerships and customer relationships, including those with named partners\nreferenced in this announcement. The foregoing list of factors is not\nexhaustive. You should carefully consider the foregoing factors and the other\nrisks and uncertainties described in the \"Risk Factors\" section of Ginkgo's\nannual report on Form 10-K filed with the U.S. Securities and Exchange\nCommission (the \"SEC\") on February 26, 2026, and other documents filed by\nGinkgo from time to time with the SEC. These filings identify and address\nother important risks and uncertainties that could cause actual events and\nresults to differ materially from those contained in the forward-looking\nstatements. Forward-looking statements speak only as of the date they are\nmade. Readers are cautioned not to put undue reliance on forward-looking\nstatements, and Ginkgo assumes no obligation and does not intend to update or\nrevise these forward-looking statements, whether as a result of new\ninformation, future events, or otherwise. Ginkgo does not give any assurance\nthat it will achieve its expectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261008805764/en/\n(https://www.businesswire.com/news/home/20261008805764/en/)\n\nGINKGO BIOWORKS INVESTOR CONTACT:\n\ninvestors@ginkgobioworks.com (mailto:investors@ginkgobioworks.com)\n\nGINKGO BIOWORKS MEDIA CONTACT:\n\npress@ginkgobioworks.com (mailto:press@ginkgobioworks.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw8qmNywa-20261008","title":"Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program","author":"Business Wire","ticker":"DNA","created":"2026-10-08T20:10:00.254Z","tickers":["DNA"],"exchange":"NYSE","article_body":"Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers,\nContributing Cloud Lab Time and Protein Testing Services to $1.5 Billion\nBreakthrough Science Program\n\nGinkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind\naccess to its autonomous laboratory in Boston to support the National Science\nFoundation’s X-Labs program. Ginkgo’s support was announced today by\nMichael Kratsios, Director of the White House Office of Science and Technology\nPolicy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C.\n\nNSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams\nof researchers, engineers, and entrepreneurs pursuing breakthrough science\nthrough milestone-based awards. Through its contribution, Ginkgo will make\ncloud lab time on its autonomous lab available to NSF X-Labs teams, giving\nresearchers remote access to robotic lab infrastructure to design, run, and\nanalyze experiments.\n\nAs part of the NSF X-Labs program, Ginkgo will offer NSF X-Labs teams its\nprotein testing services, enabling researchers to rapidly express and\ncharacterize protein designs, including those generated by AI models, without\nbuilding out their own wet lab capacity.\n\nGinkgo’s autonomous lab in Boston runs on Ginkgo’s Reconfigurable\nAutomation Carts (RACs), modular robots that combine robotic arms, maglev\nsample transport, and Catalyst software to run high-mix lab work around the\nclock. Researchers can access the lab remotely through Ginkgo Cloud Lab, which\nprovides access to a fleet of more than 70 instruments spanning sample\npreparation, liquid handling, analytical readouts, storage, and incubation.\n\nAutonomous labs are a key part of the U.S. government’s vision for American\nscience. Ginkgo already works with NSF through the Programmable Cloud\nLaboratories (PCL) Test Bed program, where it is expected to provide RACs and\nsoftware to cloud lab nodes at Caltech, the University of Maryland, and\nNorthwestern University.\n\n“Autonomous labs are a key part of the U.S. government’s vision for a\ngolden age of American science, and we’re proud to put our autonomous lab to\nwork for NSF X-Labs teams,” said Jason Kelly, co-founder and CEO of Ginkgo\nBioworks. “Robotic labs are key to competing with China and to improving the\nreproducibility and output of U.S. science. We believe robotic labs should be\nat every university and biopharma company, and programs like X-Labs show how\nquickly researchers can move when they have access to them.”\n\nResearchers interested in Ginkgo’s autonomous lab capabilities can learn\nmore and submit protocols at cloud.ginkgo.bio\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fcloud.ginkgo.bio&esheet=54618760&newsitemid=20261008805764&lan=en-US&anchor=cloud.ginkgo.bio&index=1&md5=1da2a01cb4a640608540c022c604b5b4)\n.\n\nAbout Ginkgo Bioworks\n\nGinkgo Bioworks builds the tools that make biology easier to engineer for\neveryone. The company offers autonomous laboratories that replace manual\nlaboratory work with robotics in the lab, greatly improving the productivity\nof scientists. Ginkgo’s in-house autonomous lab is also available as a\n“cloud lab” through our Datapoints and Solutions contract research\nservices. For more information, visit ginkgobioworks.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fginkgobioworks.com&esheet=54618760&newsitemid=20261008805764&lan=en-US&anchor=ginkgobioworks.com&index=2&md5=2759ac1223a0ab8755b1929795443cec)\nand ginkgobiosecurity.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fginkgobiosecurity.com&esheet=54618760&newsitemid=20261008805764&lan=en-US&anchor=ginkgobiosecurity.com&index=3&md5=d3cde321bb50c1570f0a2561c89c1593)\n, read our blog, or follow us on social media channels such as X (@Ginkgo and\n@Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or\nLinkedIn.\n\nForward-Looking Statements of Ginkgo Bioworks\n\nThis press release contains certain forward-looking statements within the\nmeaning of the federal securities laws, including statements regarding\nGinkgo’s support of the NSF X-Labs program and the capabilities and\npotential success of Ginkgo’s autonomous labs. These forward-looking\nstatements generally are identified by the words \"believe,\" \"can,\" \"project,\"\n\"potential,\" \"expect,\" \"anticipate,\" \"estimate,\" \"intend,\" \"strategy,\"\n\"future,\" \"opportunity,\" \"plan,\" \"may,\" \"should,\" \"will,\" \"would,\" \"will be,\"\n\"will continue,\" \"will likely result,\" and similar expressions.\nForward-looking statements are predictions, projections and other statements\nabout future events that are based on current expectations and assumptions\nand, as a result, are subject to risks and uncertainties. Many factors could\ncause actual future events to differ materially from the forward-looking\nstatements in this press release, including but not limited to: (i) our\nability to realize near-term and long-term cost savings associated with our\nsite consolidation plans, including the ability to terminate leases or find\nsub-lease tenants for unused facilities, (ii) volatility in the price of\nGinkgo's securities due to a variety of factors, including changes in the\ncompetitive and highly regulated industries in which Ginkgo operates and plans\nto operate, variations in performance across competitors, and changes in laws\nand regulations affecting Ginkgo's business, (iii) the ability to implement\nbusiness plans, forecasts, and other expectations, and to identify and realize\nadditional business opportunities, including with respect to our solutions and\ntools offerings, (iv) the risk of downturns in demand for products using\nsynthetic biology, (v) the uncertainty regarding the demand for passive\nmonitoring programs and biosecurity services, (vi) changes to the biosecurity\nindustry, including due to advancements in technology, emerging competition\nand evolution in industry demands, standards and regulations, (vii) the\noutcome of any pending or potential legal proceedings against Ginkgo, (viii)\nour ability to realize the expected benefits from and the success of our\nplatform programs and assets, (ix) our ability to successfully develop\nengineered cells, bioprocesses, data packages or other deliverables, (x) the\nproduct development, production or manufacturing success of our customers,\n(xi) our exposure to the volatility and liquidity risks inherent in holding\nequity interests in other operating companies and other non-cash consideration\nwe may receive for our services, (xii) the potential negative impact on our\nbusiness of our restructuring or the failure to realize the anticipated\nsavings associated therewith, (xiii) the uncertainty regarding government\nbudgetary priorities and funding allocated to government agencies, including\npotential adverse effects from the U.S. government shutdown, (xiv) our ability\nto scale, expand the capacity of, and continue to develop the capabilities of\nour autonomous lab (including Nebula) on the timelines and to the extent we\nanticipate, (xv) the pace and degree to which autonomous laboratory\ninfrastructure is adopted by, and displaces manual laboratory work in, the\nbroader life sciences and industrial biotechnology markets, (xvi) the actual\nsize, composition and growth of the addressable markets we target, which may\ndiffer materially from our estimates, (xvii) our ability to integrate our\nautonomous lab platform with third-party artificial intelligence models and\nother technologies, and the rate of development and adoption of such\ntechnologies, and (xviii) our ability to maintain and expand strategic\npartnerships and customer relationships, including those with named partners\nreferenced in this announcement. The foregoing list of factors is not\nexhaustive. You should carefully consider the foregoing factors and the other\nrisks and uncertainties described in the \"Risk Factors\" section of Ginkgo's\nannual report on Form 10-K filed with the U.S. Securities and Exchange\nCommission (the \"SEC\") on February 26, 2026, and other documents filed by\nGinkgo from time to time with the SEC. These filings identify and address\nother important risks and uncertainties that could cause actual events and\nresults to differ materially from those contained in the forward-looking\nstatements. Forward-looking statements speak only as of the date they are\nmade. Readers are cautioned not to put undue reliance on forward-looking\nstatements, and Ginkgo assumes no obligation and does not intend to update or\nrevise these forward-looking statements, whether as a result of new\ninformation, future events, or otherwise. Ginkgo does not give any assurance\nthat it will achieve its expectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261008805764/en/\n(https://www.businesswire.com/news/home/20261008805764/en/)\n\nGINKGO BIOWORKS INVESTOR CONTACT:\n\ninvestors@ginkgobioworks.com (mailto:investors@ginkgobioworks.com)\n\nGINKGO BIOWORKS MEDIA CONTACT:\n\npress@ginkgobioworks.com (mailto:press@ginkgobioworks.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-08T20:10:00.295842319Z","server_sent_at_ms":1791490200295},"received_at":"2026-10-08T20:10:00.378Z","source_url":"https://www.businesswire.com/news/home/20261008805764/en/"},"analysis":{"id":"153245","press_release_id":"164837","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["in-kind contribution with no disclosed revenue or financial terms","exposure to U.S. government budget priorities and shutdown risk noted in forward-looking statements"],"eventType":"partnership","narrative":"Ginkgo Bioworks will provide in-kind access to its Boston autonomous lab, cloud lab time, and protein testing services to researchers in the NSF X-Labs program.\n\nNSF X-Labs is a $1.5 billion, decade-long initiative funding breakthrough science through milestone-based awards; Ginkgo's contribution was announced by OSTP Director Michael Kratsios in Washington, D.C.\n\nThe deal builds on Ginkgo's existing NSF PCL Test Bed work with Caltech, Maryland, and Northwestern and validates its autonomous lab strategy, though no direct revenue was disclosed.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Government validation of Ginkgo's autonomous lab platform via $1.5B NSF X-Labs program, but financial impact undisclosed."},"keyFigures":{"dealValueUsd":"$1.5 billion","customDimensions":{"instruments_in_fleet":70,"program_duration_years":10}},"quotedText":"Autonomous labs are a key part of the U.S. government's vision for a golden age of American science, and we're proud to put our autonomous lab to work for NSF X-Labs teams","namedEntities":{"people":[{"name":"Michael Kratsios","role":"Director, White House Office of Science and Technology Policy"},{"name":"Jason Kelly","role":"co-founder and CEO of Ginkgo Bioworks"}],"products":["Ginkgo autonomous lab","Reconfigurable Automation Carts (RACs)","Catalyst software","Ginkgo Cloud Lab","protein testing services"],"companies":[{"name":"Ginkgo Bioworks","ticker":"DNA","relationship":"filer/participant"},{"name":"National Science Foundation (NSF)","relationship":"program sponsor"},{"name":"White House Office of Science and Technology Policy","relationship":"government endorser"},{"name":"Caltech","relationship":"cloud lab node participant"},{"name":"University of Maryland","relationship":"cloud lab node participant"},{"name":"Northwestern University","relationship":"cloud lab node participant"}],"dollarAmounts":[{"amount":"$1.5 billion","context":"NSF X-Labs decade-long breakthrough science program"}]},"materialImpact":{"score":2,"reasoning":"Ginkgo contributes in-kind cloud lab time and protein testing services to the NSF X-Labs program, extending its existing government partnerships and validating its autonomous lab platform, but no revenue figures or financial terms are disclosed. Positive visibility rather than a market-moving financial event."},"tickerRelevance":{"others":[],"primary":"DNA"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"partnership-with-government-program","financialImpact":"in-kind, undisclosed","endorsementValue":"White House/OSTP visibility"}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Ginkgo Bioworks will provide in-kind access to its Boston autonomous lab, cloud lab time, and protein testing services to researchers in the NSF X-Labs program.\n\nNSF X-Labs is a $1.5 billion, decade-long initiative funding breakthrough science through milestone-based awards; Ginkgo's contribution was announced by OSTP Director Michael Kratsios in Washington, D.C.\n\nThe deal builds on Ginkgo's existing NSF PCL Test Bed work with Caltech, Maryland, and Northwestern and validates its autonomous lab strategy, though no direct revenue was disclosed.","key_figures":{"dealValueUsd":"$1.5 billion","customDimensions":{"instruments_in_fleet":70,"program_duration_years":10}},"named_entities":{"people":[{"name":"Michael Kratsios","role":"Director, White House Office of Science and Technology Policy"},{"name":"Jason Kelly","role":"co-founder and CEO of Ginkgo Bioworks"}],"products":["Ginkgo autonomous lab","Reconfigurable Automation Carts (RACs)","Catalyst software","Ginkgo Cloud Lab","protein testing services"],"companies":[{"name":"Ginkgo Bioworks","ticker":"DNA","relationship":"filer/participant"},{"name":"National Science Foundation (NSF)","relationship":"program sponsor"},{"name":"White House Office of Science and Technology Policy","relationship":"government endorser"},{"name":"Caltech","relationship":"cloud lab node participant"},{"name":"University of Maryland","relationship":"cloud lab node participant"},{"name":"Northwestern University","relationship":"cloud lab node participant"}],"dollarAmounts":[{"amount":"$1.5 billion","context":"NSF X-Labs decade-long breakthrough science program"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T20:10:06.625Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"partnership-with-government-program","financialImpact":"in-kind, undisclosed","endorsementValue":"White House/OSTP visibility"}},"durationMs":6180,"modelName":"glm-5.3-flashx"}}